Cepheid's Next-Generation MRSA Screening Test Gets CE Mark | GenomeWeb

NEW YORK (GenomeWeb) – Cepheid today announced it has received CE marking for a next-generation version of its molecular test for methicillin-resistant Staphylococcus aureus.

The Xpert MRSA NxG identifies mecA- and mecC-containing strains of MRSA as well emerging SCCmec subtypes. It has enhanced features, including room-temperature storage, validation on multiple swab types, and the ability to rule out empty cassette strains, the firm noted in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.